Ubs Group Ag Petros Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$0.68 - $1.49 $3,277 - $7,181	-4,820 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.07 - $3.36 $2,964 - $9,310	2,771 Added 135.24%	4,820 $8,000
Q4 2021 Feb 14, 2022	SELL	$1.33 - $4.09 $2,078 - $6,392	-1,563 Reduced 43.27%	2,049 $7,000
Q3 2021 Nov 15, 2021	BUY	$1.82 - $3.2 $4,857 - $8,540	2,669 Added 283.03%	3,612 $7,000
Q2 2021 Aug 13, 2021	BUY	$2.87 - $4.11 $2,706 - $3,875	943 New	943 $3,000
Q1 2021 May 12, 2021	SELL	$2.85 - $4.6 $8,170 - $13,188	-2,867 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$3.24 - $4.68 $9,289 - $13,417	2,867 New	2,867 $13,000

Ticker PTPI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 20,708,000
Market Cap $5.18M
Description
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for th...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.